Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA - Martin, Tom; Richardson, Paul G; Facon, Thierry; Moreau, Philippe; Perrot, Aurore; Spicka, Ivan; Bisht, Kamlesh; Inchauspé, Marlene; Casca, France; Macé, Sandrine; Van de Velde, Helgi; Suzuki, Kenshi (Haematologica, 2022)
Keywords: Thalidomide; humanizované monoklonální protilátky; Antibodies, Monoclonal, Humanized; dexamethason; thalidomid; Neoplasm Recurrence, Local; Dexamethasone; lidé; mnohočetný myelom; Multiple Myeloma; Neoplasms, Plasma Cell; lokální recidiva nádoru; Antineoplastic Combined Chemotherapy Protocols; nádory plazmocelulární; Humans; protokoly protinádorové kombinované chemoterapie